학술논문

Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72‐associated amyotrophic lateral sclerosis
Document Type
article
Source
Annals of Neurology. 82(1)
Subject
Biomedical and Clinical Sciences
Neurosciences
Clinical Sciences
ALS
Brain Disorders
Rare Diseases
Neurodegenerative
Clinical Research
4.1 Discovery and preclinical testing of markers and technologies
Detection
screening and diagnosis
Neurological
Good Health and Well Being
Adult
Aged
Aged
80 and over
Amyotrophic Lateral Sclerosis
Biomarkers
C9orf72 Protein
Case-Control Studies
Disease Progression
Female
Humans
Male
Middle Aged
Neurofilament Proteins
Phosphorylation
Proteins
Survival Analysis
Young Adult
C9ORF72 Neurofilament Study Group
Neurology & Neurosurgery
Clinical sciences
Language
Abstract
As potential treatments for C9ORF72-associated amyotrophic lateral sclerosis (c9ALS) approach clinical trials, the identification of prognostic biomarkers for c9ALS becomes a priority. We show that levels of phosphorylated neurofilament heavy chain (pNFH) in cerebrospinal fluid (CSF) predict disease status and survival in c9ALS patients, and are largely stable over time. Moreover, c9ALS patients exhibit higher pNFH levels, more rapid disease progression, and shorter survival after disease onset than ALS patients without C9ORF72 expansions. These data support the use of CSF pNFH as a prognostic biomarker for clinical trials, which will increase the likelihood of successfully developing a treatment for c9ALS. Ann Neurol 2017;82:139-146.